Chicago – July 29, 2026
The Trump administration is reportedly preparing to end a federal subsidy that has helped stabilize Medicare prescription drug plans, according to a report by The Wall Street Journal. The subsidy, introduced to limit premium increases and encourage insurer participation, has supported millions of seniors enrolled in Medicare Part D plans.
If the proposal moves forward, insurers could face higher costs, raising concerns that some beneficiaries may experience increased monthly premiums or changes to their prescription drug coverage. Health policy experts say the impact will depend on how insurers respond and whether alternative measures are introduced to maintain affordability.
Administration officials argue that temporary subsidies were never intended to become permanent and that the Medicare program should operate under a more sustainable financial framework. Supporters say ending the payments could reduce federal spending and encourage greater market competition.
The proposal has not yet been finalized, and any changes would likely face scrutiny from lawmakers, healthcare providers, insurers, and senior advocacy groups before taking effect.
